Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival-Reference-Cited by-同舟云学术

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Published:2012-07-29 Issue:8 Volume:18 Page:1254-1261
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Walter Steffen,Weinschenk Toni,Stenzl Arnulf,Zdrojowy Romuald,Pluzanska Anna,Szczylik Cezary,Staehler Michael,Brugger Wolfram,Dietrich Pierre-Yves,Mendrzyk Regina,Hilf Norbert,Schoor Oliver,Fritsche Jens,Mahr Andrea,Maurer Dominik,Vass Verona,Trautwein Claudia,Lewandrowski Peter,Flohr Christian,Pohla Heike,Stanczak Janusz J,Bronte Vincenzo,Mandruzzato Susanna,Biedermann Tilo,Pawelec Graham,Derhovanessian Evelyna,Yamagishi Hisakazu,Miki Tsuneharu,Hongo Fumiya,Takaha Natsuki,Hirakawa Kosei,Tanaka Hiroaki,Stevanovic Stefan,Frisch Jürgen,Mayer-Mokler Andrea,Kirner Alexandra,Rammensee Hans-Georg,Reinhardt Carsten,Singh-Jasuja Harpreet

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.2883.pdf

Reference71 articles.

1. Kantoff, P.W. et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099–1105 (2010).

2. Schwartzentruber, D.J. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119–2127 (2011).

3. Schuster, S.J. et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787–2794 (2011).

4. Weinschenk, T. et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62, 5818–5827 (2002).

5. Singh-Jasuja, H., Emmerich, N.P. & Rammensee, H.G. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 53, 187–195 (2004).

Cited by 693 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives;International Immunopharmacology;2024-12

2. iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens;Frontiers in Oncology;2024-08-26

3. Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective;Vaccines;2024-08-22

4. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine;Nature Communications;2024-08-11

5. Increased circulating polymorphonuclear myeloid-derived suppressor cells are associated with prognosis of metastatic castration-resistant prostate cancer;Frontiers in Immunology;2024-06-03